Coherus BioSciences, Inc. (CHRS)

Market Cap	126.73M
Revenue (ttm)	304.34M
Net Income (ttm)	-450,000
Shares Out	115.21M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,704,367
Open	0.820
Previous Close	0.822
Day's Range	0.810 - 1.130
52-Week Range	0.660 - 3.700
Beta	0.69
Analysts	Strong Buy
Price Target	6.13 (+457.27%)
Earnings Date	Nov 6, 2024

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal ant...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 306
• Stock Exchange: NASDAQ
• Ticker Symbol: CHRS
• Website: https://www.coherus.com

Financial Performance

In 2023, Coherus BioSciences's revenue was $257.24 million, an increase of 21.89% compared to the previous year's $211.04 million. Losses were -$237.89 million, -18.46% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price forecast is $6.13, which is an increase of 457.27% from the latest price.

Price Target

$6.13

(457.27% upside)

Analyst Consensus: Strong Buy